Arcturus Therapeutics Stock Jumps On mRNA COVID-19 Vaccine Update

Arcturus Therapeutics Holdings Inc ARCT reported a Q2 EPS loss of $(2.07), beating the consensus of $(2.14).
The cash balance totaled $433.6 million. After the end of the quarter, Arcturus received the remaining $30 million of upfront payment from Vinbiocare.
The company's cash position is sufficient to support operations for more than two years based on the current pipeline.
In its Q2 release, Arcturus Therapeutics said that preclinical data of its COVID-19 mRNA vaccine candidate, ARCT-154, demonstrated strong neutralizing immunogenicity in non-human primates to the four variants.
ARCT-154 elicits 14.4 to 25.9-fold higher neutralizing antibody titers than ARCT-021 in non-human primates, including an observed increase of 17.8-fold higher neutralizing antibody titers against the Delta variant.
Arcturus has advanced ARCT-154 toward multiple clinical development studies.
The ARCT-154 vaccine targets the D614G spike protein mutation that has become dominant globally.
Last week, the Vietnam Ministry of Health signed off Arcturus's trial application to advance ARCT-154 targeting variants of concern.
The company also said that ARCT-021 had been selected by a global entity to be included in a multinational COVID-19 Phase 3 vaccine trial.
The placebo-controlled study will evaluate a 5-mcg dose of ARCT-021 administered as a single injection regimen. The Phase 3 study will be sponsored and funded by the entity.
Price Action: ARCT shares are up 24.80% at $60.22 during the premarket session on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs

Comments

Earnings Calendar

Never Miss Important Catalysts

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga